Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Capitolis Liquid Global Markets LLC

Capitolis Liquid Global Markets LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 80,000 shares of the biopharmaceutical company’s stock after acquiring an additional 5,000 shares during the quarter. Capitolis Liquid Global Markets LLC’s holdings in Regeneron Pharmaceuticals were worth $61,750,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. WPG Advisers LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Kemnay Advisory Services Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Finally, Entrust Financial LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ:REGN opened at $607.93 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $503.25 and a 52 week high of $821.11. The company’s 50 day moving average is $683.13 and its two-hundred day moving average is $734.34. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market cap of $64.27 billion, a PE ratio of 14.81, a P/E/G ratio of 1.35 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the firm posted $8.22 EPS. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Royal Bank Of Canada cut their target price on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research note on Monday, May 18th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Canaccord Genuity Group cut their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.